Table 1.
Characteristics of individual study.
| Study | Year | Region | No. of patients (female) | Ages Mean(SD) | Design | Classification of urinary incontinence | Basic diseases | Intervention | Follow-up (weeks) |
|---|---|---|---|---|---|---|---|---|---|
| Schurch | 2005 | Switzerland | 59(23) | 41 | Randomized, doubled-blind | NDO | MS:6, SCI:53 | Group 1: BTX-A 300U (19); Group 2: BTX-A 200U (19); Group 3: Placebo (21) | 6 |
| Sahai | 2007 | UK | 34(19) | 49.8, 50.8 | Randomized, doubled-blind | IOAB | NA | Group 1: BTX-A 200U (16); Group 2: Placebo (18) | NA |
| Brubaker | 2008 | USA | 43 | 64.7(14.5), 69.2(13.5) | Randomized, doubled-blind | IOAB | NA | Group 1: BTX-A 200U (28); Group 2: Placebo (15) | NA |
| Cohen | 2009 | USA | 44 | NA | Randomized, doubled-blind | IOAB | NA | Group 1: BTX-A 150U (22); Group 2: BTX-A 100U (22) | NA |
| Dmochowski | 2010 | USA | 313(288) | 58.8 | Randomized, doubled-blind | IOAB | NA | Group 1: BTX-A 50U (56); Group 2: BTX-A 100U (55); Group 3: BTX-A 150U (50); Group 4: BTX-A 200U (52); Group 5: BTX-A 300U (55); Group 6: Placebo (43) | NA |
| Rovner | 2011 | USA | 313(288) | 58.8 | Randomized, doubled-blind | IOAB | NA | Group 1: BTX-A 50U (57); Group 2: BTX-A 100U (54); Group 3: BTX-A 150U (49); Group 4: BTX-A 200U (53); Group 5: BTX-A 300U (56); Group 6: Placebo (44) | 12, 36 |
| Cruz | 2011 | Portugal | 275(155) | 46(13.1), 44.4(13.9), 46.9(13.4) | Randomized, doubled-blind | NDO | MS:154, SCI:121 | Group 1: BTX-A 200U (92); Group 2: BTX-A 300U (91); Group 3: Placebo (92) | 2, 6, 12 |
| Herschorn | 2011 | Canada | 57(23) | 42.8 | Randomized, doubled-blind | NDO | MS:19, SCI:38 | Group 1: BTX-A 300U (28); Group 2: Placebo (29) | NA |
| Altaweel | 2011 | Saudi Arabia | 22 | NA | Randomized, doubled-blind | IOAB | NA | Group 1: BTX-A 200U (11); Group 2: BTX-A 100U (11) | NA |
| Denys | 2012 | France | 199(87) | 62.3, 61.7 | Randomized, doubled-blind | IOAB | NA | Group 1: BTX-A 50U (23); Group 2: BTX-A 100U (23); Group 3: BTX-A 150U (30); Group 4: Placebo (31) | 12 |
| Ginsberg | 2012 | USA | 416(245) | 46(13) | Randomized, doubled-blind | NDO | MS:227, SCI:189 | Group 1: BTX-A 200U (135); Group 2: BTX-A 300U (127); Group 3: Placebo (145) | 6 |
| Rovner | 2013 | USA | 691(400) | 45.9, 45.6, 46.2 | Randomized, doubled-blind | NDO | MS:103, SCI:138 | Group 1: BTX-A 200U (227); Group 2: BTX-A 300U (223); Group 3: Placebo (241) | 6 |
| Nitti | 2013 | USA | 557(497) | 61.7(12.7), 61(13.1) | Randomized, doubled-blind | IOAB | NA | Group 1: BTX-A 100U (278); Group 2: Placebo (272) | 12 |
| Kennelly | 2013 | USA | 387(233) | 46.4 | Randomized, doubled-blind | NDO | SCI, MS | Group 1: BTX-A 300U (185); Group 2: BTX-A 200U (202) | 6 |
| Ginsberg | 2013 | USA | 381(311) | 49.7(12.1), 49.9(10.7), 50.2(10.7) | Randomized, doubled-blind | NDO | MS:381, SCI:310 | Group 1: BTX-A 200U(227); Group 2: BTX-A 300U(223); Group 3: Placebo (241) | 6 |
| Chapple | 2013 | UK | 548(473) | 59.5(15.5), 59.2(14.1) | Randomized, doubled-blind | IOAB | NA | Group 1: BTX-A 100U (277); Group 2: Placebo (271) | NA |
| Sievert | 2014 | Germany | 1105(970) | 60.6(14.2), 60.1(13.6) | Randomized, doubled-blind | IOAB | NA | Group 1: BTX-A 100U (557); Group 2: Placebo (548) | NA |
| Chen | 2014 | Taiwan | 72(29) | 41.5 | Randomized, doubled-blind | NDO | SCI | Group 1: BTX-A 300U (34); Group 2: BTX-A 200U (38) | NA |
| Abdelwahab | 2015 | Egypt | 80(63) | 31.35, 30.22 | Randomized, doubled-blind | IOAB | NA | Group 1: BTX-A 100U (40); Group 2: BTX-A 200U (40) | 12, 36 |
BTX-A, Botulinum toxin A; NDO, Neurogenic detrusor overactivity; IOAB, Idiopathic overactive bladder; MS, Multiple sclerosis; SCI, Spinal cord injury; NA, Not available.